Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C

被引:0
作者
Moana Gelu-Simeon [1 ]
Aurore Burlaud [1 ]
Jacques Young [2 ]
Gilles Pelletier [1 ]
Catherine Buffet [1 ]
机构
[1] Department of Hepatology and Gastroenterology,Bicetre Hospital,78 rue du General Leclerc,Le Kremlin-Bicetre 94275,France
[2] Department of Endocrinology,Bicetre Hospital,78 rue du General Leclerc,Le Kremlin-Bicetre 94275,France
关键词
Chronic hepatitis C; Interferon alpha; Predictive factors; Thyroid disorder;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
AIM:To study predictive factors of thyroid dysfunction associated with interferon-alpha(IFNα) therapy in chronic hepatitis C(CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction.METHODS:We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNα from 1999 to 2004.RESULTS:Thyroid disorder developed in 30/301(10%) patients with a mean delay of 6 ± 3.75 mo:13 patients had hyperthyroidism,11 had hypothyroidism,and 6 had biphasic evolution.During a mean follow-up of 41.59 ± 15.39 mo,9 patients with hyperthyroidism,3 with hypothyroidism,and 4 with biphasic evolution normalized thyroid function in 7.88 ± 5.46 mo.Recovery rate of dysthyroidism was not modified by treatment discontinuation,but was better for patients with negative thyroid antibodies before antiviral treatment(P = 0.02).Women had signif icantly more dysthyroidism(P = 0.05).Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism(P < 0.0003 and P = 0.0003,respectively).In a multivariate model,low fibrosis was found to be a predictive factor of dysthyroidism(P = 0.039).CONCLUSION:In this monocentric population of CHC,dysthyroidism,especially hyperthyroidism,developed in 10% of patients.Low fibrosis was found to be a predictive factor of dysthyroidism.Thyroid disorder recovered in 16/30 patients(53%) and recovery was better in the non-autoimmune form.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 6 条
  • [1] Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C
    Moncoucy, X
    Leymarie, F
    Delemer, B
    Lévy, S
    Bernard-Chabert, B
    Bouché, O
    Jolly, D
    Diebold, MD
    Cadiot, G
    Thiéfin, G
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2005, 29 (04): : 339 - 345
  • [2] Interferon-α-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects[J] . C Carella,G Mazziotti,G Amato,L E. Braverman,E Roti.The Journal of Clinical Endocrinology & Metabolism . 2004 (8)
  • [3] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial[J] . Michael P Manns,John G McHutchison,Stuart C Gordon,Vinod K Rustgi,Mitchell Shiffman,Robert Reindollar,Zachary D Goodman,Kenneth Koury,Mei-Hsiu Ling,Janice K Albrecht.The Lancet . 2001 (9286)
  • [4] Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy
    Deutsch, M
    Dourakis, S
    Manesis, EK
    Gioustozi, A
    Hess, G
    Horsch, A
    Hadziyannis, S
    [J]. HEPATOLOGY, 1997, 26 (01) : 206 - 210
  • [5] Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha
    Roti, E
    Minelli, R
    Giuberti, T
    Marchelli, S
    Schianchi, C
    Gardini, E
    Salvi, M
    Fiaccadori, F
    Ugolotti, G
    Neri, TM
    Braverman, LE
    [J]. AMERICAN JOURNAL OF MEDICINE, 1996, 101 (05) : 482 - 487
  • [6] An algorithm for the grading of activity in chronic hepatitis C
    Bedossa, P
    Poynard, T
    [J]. HEPATOLOGY, 1996, 24 (02) : 289 - 293